Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07531511) titled 'SLC6A1-NDD Prospective Longitudinal Natural History Study' on April 8.
Study Type: Observational
Primary Sponsor: UCB Biopharma SRL
Condition:
SLC6A1 Neurodevelopmental Disorder (NDD)
Developmental and Epileptic Encephalopathies
Recruitment Status: Not recruiting
Date of First Enrollment: April 2026
Target Sample Size: 60
To know more, visit https://clinicaltrials.gov/study/NCT07531511
Disclaimer: Curated by HT Syndication....